Compare Teradyne, Inc. (TER) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teradyne, Inc. vs Zoetis Inc — how do they compare? Teradyne, Inc. trades at $383.48 (market cap $55.82B), while Zoetis Inc trades at $73.51 (market cap $30.40B). The key difference: Teradyne, Inc. is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.88%). Which is the better fit depends on your goals.
| TER | ZTS | |
|---|---|---|
Market Cap | $55.82B | $30.40B |
Sector | Technology | Health |
52-Week High | $483.84 | $150.61 |
52-Week Low | $112.24 | $71.91 |
Enterprise Value | $55.56B | $37.96B |
Dividend Yield | 0.15% | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Teradyne (TER) trades at $372.06, up 4.21% on the day, with a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $3.19B in 2025, and net income margin stands at 25.77%. Analyst sentiment is positive, with a consensus price target of $474.78 and no sell ratings among 31 analysts. Recent news highlights surging demand for UltraFLEXplus systems driven by AI and data center growth.
The outlook for TER is favorable, supported by robust AI-driven demand, earnings momentum, and institutional accumulation. Key risks include competitive pressures from KLA and Cohu, reliance on semiconductor cycles, and execution challenges in scaling operations. The stock offers upside potential but remains sensitive to tech sector volatility and macroeconomic conditions affecting capital expenditure trends.
Zoetis (ZTS) trades at $73.60, down 2.92% amid bearish technical signals and mixed earnings. The stock faces pressure from weakening U.S. companion animal sales and competitive headwinds, though profitability remains strong with 71.67% gross margins and 27.69% net income margin. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a guidance cut. Analyst consensus is divided with 45% Buy ratings and a $93.40 price target, suggesting 27% upside from current levels.
The outlook balances valuation appeal (P/E of 12) against near-term operational challenges. Investment opportunity lies in market dominance and robust cash flow generation, while risks include sustained pet health demand softness and competitive pricing pressure. The stock trades near support at $73, with institutional sentiment mixed amid recent portfolio adjustments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
